Novartis Reports Strong Q4, Driven by Entresto and Kesimpta Sales
Novartis announced a surge in adjusted net income for the fourth quarter, exceeding analysts' expectations. The growth was fueled by robust sales of its heart failure drug Entresto and multiple sclerosis drug Kesimpta.
Adjusted net income surged 26% to $3.93 billion, surpassing the consensus estimate of $3.64 billion. Entresto, facing generic competition later this year, saw a 33% revenue increase to $2.18 billion, outpacing expectations.
Kesimpta, a self-injectable MS treatment, saw a notable 50% sales jump to $950 million, also exceeding market estimates.
Novartis projects a "high single to low double-digit" percentage increase in 2025 operating income, excluding currency fluctuations. This follows a 22% increase in 2024.